About Climb Bio Inc
- Industry: Biotechnology
- Exchange: NASDAQ NMS - GLOBAL MARKET
- Country: US
- Website: https://climbbio.com/
Frequently Asked Questions
What is the 52-week range for CLYM?
The 52-week high is $18.33 and the 52-week low is $1.54.
What is the P/E ratio for CLYM?
The P/E ratio data is currently unavailable.
What is the dividend yield for CLYM?
This company does not currently pay a dividend or the data is unavailable.
What is the Return on Equity (ROE)?
The trailing twelve months (TTM) Return on Equity is -31.79%.
What is the Net Profit Margin?
Net Margin data is currently unavailable.
What is the Price to Book (P/B) Ratio?
The annual Price to Book ratio stands at 1.70.
Analyst Recommendation Trends
Wall Street analyst consensus for CLYM over the last few months:
Latest CLYM News
Climb Bio to Present New Data at American Society of Nephrology (ASN) Kidney Week 2026 for CLYM116 and Budoprutug
Preliminary Phase 2 data from the ongoing PrisMN study of budoprutug in primary membranous nephropathy selected for oral presentation Presentations on CLYM116 and budoprutug programs highlight advancements across the portfolio WELLESLEY HILLS, Mass., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (Nasdaq: CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and b
Climb Bio To Present New Data For Its CLYM116, Budoprutug Programs Across Three Immune-Mediated Kidney Diseases At American Society Of Nephrology Kidney Week 2026
Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that it will present new clinical data for its CLYM116 and
Raymond James Updates Healthcare Top Picks for October
Investing.com -- Raymond James has updated its Healthcare Top Picks list for October, adding three new stocks while removing others from the monthly selection. The firm added Xencor, Calyxt, and UnitedHealth Group to replace Relay Therapeutics, Tyra Biosciences, and Oscar Health.
The Biggest Losers In Biotech — And It Had Nothing To Do With 'Compelling,' 'Best-In-Disease' Data
Biotech stocks widely slumped Wednesday, with Rapport Therapeutics, Climb Bio and Cullinan Therapeutics among some of the hardest-hit names.
Oppenheimer Maintains Outperform on Climb Bio, Raises Price Target to $25
Oppenheimer analyst Leland Gershell maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $18 to $25.
Robinhood To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Tuesday
Analysts raised targets for NOW, HOOD, MSTR, ABNB and CLYM, while cutting APP and IONS; ratings largely remain positive.
HC Wainwright & Co. Maintains Buy on Climb Bio, Raises Price Target to $30
HC Wainwright & Co. analyst Raghuram Selvaraju maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $24 to $30.
B. Riley Securities Reiterates Buy on Climb Bio, Raises Price Target to $30
B. Riley Securities analyst Mayank Mamtani reiterates Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $26 to $30.
Ionis’ rare neurology drug approved; Pfizer inks an ADC deal
Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.
Why Climb Bio, Up 1,300% Over 17 Months, Just Took A Tumble
Climb Bio reversed course downward Thursday despite potential "best-in-class" data for its experimental kidney disease treatment.
Climb Bio Phase I Data Backs 12-Week Dosing Plan for IgA Nephropathy Drug
Climb Bio (NASDAQ:CLYM) presented phase I data for CLYM116, an anti-APRIL “sweeper” antibody being developed for IgA nephropathy, and said the results support advancing the program into an ongoing phase II study in China. The company said CLYM116 is designed to bind circulating APRIL, bring the tar
BTIG Maintains Buy on Climb Bio, Raises Price Target to $32
BTIG analyst Julian Harrison maintains Climb Bio (NASDAQ:CLYM) with a Buy and raises the price target from $20 to $32.
Baird Maintains Outperform on Climb Bio, Raises Price Target to $25
Baird analyst Colleen Kusy maintains Climb Bio (NASDAQ:CLYM) with a Outperform and raises the price target from $21 to $25.
Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule
Climb Bio announced positive Phase 1 data for CLYM116 and outlined its strategy to advance the IgA nephropathy candidate into Phase 3.
Climb Bio Shares Rise 17% After Phase 1 CLYM116 Trial Data
Climb Bio, Inc. (NASDAQ:CLYM) shares rose 17% on Thursday after the clinical-stage biotechnology company released Phase 1 trial data for CLYM116, its anti-APRIL monoclonal antibody being developed for IgA nephropathy.
Related Stocks (Peers)
Recent Insider Transactions
| Date | Name | Shares Changed | Price | Value |
|---|---|---|---|---|
| 2026-09-15 | Thomas Stephen Basil | -100,000 | $13.6682 | $1,366,820 |
| 2026-06-29 | Celebi Breanna Maurine | +70,284 | - | - |
| 2026-06-29 | RA CAPITAL MANAGEMENT, L.P. | +70,284 | - | - |
| 2026-06-05 | Levin Andrew David | +40,000 | - | - |
| 2026-06-05 | Thomas Stephen Basil | +40,000 | - | - |
| 2026-06-05 | Dunn Judith | +40,000 | - | - |
| 2026-06-05 | Cumbo Alexander | +40,000 | - | - |
| 2026-06-05 | Drapkin Kimberlee C | +40,000 | - | - |
| 2026-06-05 | RA Capital Healthcare Fund LP | +40,000 | - | - |
| 2026-06-05 | WILLIAMS DOUGLAS E | +40,000 | - | - |
| 2026-04-29 | RA Capital Healthcare Fund LP | +2,106,000 | $9.4999 | $20,006,789 |
| 2026-02-26 | Thomas Stephen Basil | -16,313 | $7.006 | $114,289 |
| 2026-02-25 | Thomas Stephen Basil | -33,687 | $7.0046 | $235,964 |
| 2026-02-13 | Thomas Stephen Basil | -10,000 | $5.8141 | $58,141 |
| 2026-02-12 | Thomas Stephen Basil | -90,000 | $5.2332 | $470,988 |
| 2026-01-06 | Wilson Perrin Megan | +300,000 | - | - |
| 2026-01-06 | ALTSCHULLER Susan | +142,500 | - | - |
| 2026-01-06 | Driscoll Cindy | +100,000 | - | - |
| 2026-01-06 | Brennan Aoife | +700,000 | - | - |
| 2026-01-05 | RA Capital Healthcare Fund LP | +7,111 | $3.5 | $24,889 |
| 2025-12-12 | RA Capital Healthcare Fund LP | +101,462 | $2.86 | $290,181 |
| 2025-12-11 | RA Capital Healthcare Fund LP | +20,440,000 | - | - |
| 2025-12-11 | RA Capital Healthcare Fund LP | +213,099 | $2.18 | $464,556 |
| 2025-12-11 | RA Capital Healthcare Fund LP | -20,440,000 | - | - |